文献速递疼痛医学神经外科与老年麻醉

慢性疼痛、镇痛药与认知状态:一项综合孟德尔随机化研究

Chronic Pain, Analgesics, and Cognitive Status: A Comprehensive Mendelian Randomization Study.
PubMed 文献 · Anesth Analg · 2023-05-12

该研究采用双向孟德尔随机化方法,纳入9种慢性疼痛、4类镇痛药及5种认知状态的全基因组关联研究汇总数据,发现多部位慢性疼痛与认知功能下降存在因果关联,而痴呆患者对乙酰苯胺类和NSAIDs的暴露较低,提示其疼痛治疗可能不足。

要点

  • 多部位慢性疼痛可预测未来认知功能下降,未发现认知状态对慢性疼痛的反向因果效应。
  • 未观察到镇痛药与认知状态之间的显著因果关联。
  • AD和LBD患者对乙酰苯胺类和NSAIDs的暴露显著降低,提示可能存在疼痛治疗不足。

核心结论

  • 多部位慢性疼痛与认知功能下降存在因果关联,且认知状态对慢性疼痛无显著反向效应。
  • 未发现镇痛药使用与认知状态之间的显著因果关联。
  • AD和LBD患者对乙酰苯胺类和NSAIDs的暴露较低,提示痴呆患者可能未得到充分的疼痛治疗。

研究设计与样本

  • 研究采用双向孟德尔随机化分析,纳入9种慢性疼痛、4类镇痛药及5种认知状态的GWAS汇总统计量。
  • 使用强遗传工具(P < .001),采用逆方差加权法计算估计值,Benjamini-Hochberg法校正多重检验(P < .05为显著)。

主要发现

  • 多部位慢性疼痛与较差的认知功能相关(OR 0.69,95%CI 0.53-0.89,P = .043)。
  • 未发现认知状态对慢性疼痛的显著反向效应。
  • AD患者对乙酰苯胺类暴露较低(OR 0.97,95%CI 0.94-0.99,P = .034),对NSAIDs暴露较低(OR 0.96,95%CI 0.93-0.98,P = .012)。
  • LBD患者对乙酰苯胺类暴露较低(OR 0.97,95%CI 0.96-0.99,P = .012),对NSAIDs暴露较低(OR 0.98,95%CI 0.96-0.99,P = .034)。

关键数值与推荐

  • 多部位慢性疼痛与认知功能下降的因果关联具有统计学显著性(校正后P = .043)。
  • AD和LBD患者对乙酰苯胺类和NSAIDs的暴露降低均具有统计学显著性(校正后P < .05)。

临床怎么用

  • 对多部位慢性疼痛患者应关注认知功能变化,必要时进行认知评估。
  • 痴呆患者应定期评估疼痛并合理使用镇痛药,避免疼痛治疗不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies have suggested an intricate relationship among chronic pain (CP), use of analgesics, and cognitive status, but it remains unclear whether these associations are of a causal nature. METHODS: To investigate the causal relationship among them, summary statistics of 9 types of CP (headache, hip, neck/shoulder, stomach/abdominal, back, knee, facial, general, and multisite CP), analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs], opioids, salicylic acid and derivatives, and anilides), and cognitive status (cognitive function, Alzheimer's disease [AD], vascular dementia, Lewy body dementia [LBD], and dementia) were included in this Mendelian randomization (MR) study. As both CP and analgesic use were associated with cognitive status and vice versa, we performed a bidirectional MR analysis between CP or analgesics and dementia using strong genetic instruments ( P < .001) identified from genome-wide association studies (GWAS). The inverse-variance weighted method was applied to calculate estimates. The MR estimated odds ratio (OR) was interpreted as odds of outcome per unit increase in the exposure. The Benjamini-Hochberg method was applied to adjust the P value for multiple testing, and P < .05 means statistically significant. RESULTS: Multisite CP (MCP) was associated with worse cognitive function (OR [95% confidence interval], 0.69 [0.53-0.89], P = .043), but no significant reverse effect of cognitive status on CP was found. There were no significant associations observed between analgesics and cognitive status. Unexpectedly, patients with AD and LBD had significantly lower exposure to anilides (AD: OR = 0.97 [0.94-0.99], P = .034; LBD: OR = 0.97 [0.96-0.99], P = .012) and NSAIDs (AD: OR = 0.96 [0.93-0.98], P = .012; LBD: OR = 0.98 [0.96-0.99], P = .034). CONCLUSIONS: Our findings indicate that an elevated number of CP sites predict future cognitive decline. Patients with dementia had lower exposure to anilides and NSAIDs, suggesting that they might not be adequately medicated for pain.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Guo X, Hou C, Tang P, et al. Chronic Pain, Analgesics, and Cognitive Status: A Comprehensive Mendelian Randomization Study. Anesth Analg. 2023. PMID: 37171986. doi:10.1213/ANE.0000000000006514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。